Aktienanalyse zu Anteris Technologies Global Corp (AVR)AVRAnteris Technologies Global Corp

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company's ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system. It operates in the Healthcare sector.

Anteris Technologies is currently not a strong buy due to its low current price of $5.87 and a concerning RSI of 22.052, indicating oversold conditions. The company has a significant gross margin of 76.91%, but it also faces substantial risks with a negative net income of -28,794,000 USD in Q2 2026. The analyst price target of $10 suggests potential upside, but the current financial instability and negative cash flows warrant caution.